Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the treatment of patients who are women with natural or artificially induced postmenopausal endocrine status with advanced breast cancer after relapse or disease progression. This therapy regimen lists hormone receptor-negative status as an exclusion criteria.
This is written in the approval document as:
Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.
Citation
Letrozole Monotherapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Letrozole | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Letrozole | |
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Letrozole |